Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis

Treatments of metastatic melanoma underwent an impressive development over the past few years, with the emergence of small molecule inhibitors targeting mutated proteins, such as BRAF, NRAS, or cKIT. However, since a significant proportion of patients acquire resistance to these therapies, new strat...

Descripción completa

Detalles Bibliográficos
Autores principales: Soumoy, Laura, Schepkens, Corentin, Krayem, Mohammad, Najem, Ahmad, Tagliatti, Vanessa, Ghanem, Ghanem E., Saussez, Sven, Colet, Jean-Marie, Journe, Fabrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280989/
https://www.ncbi.nlm.nih.gov/pubmed/32455924
http://dx.doi.org/10.3390/cancers12051323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280989/
https://www.ncbi.nlm.nih.gov/pubmed/32455924
http://dx.doi.org/10.3390/cancers12051323

Ejemplares similares